![Endless RNA Endless RNA](https://static.packgene.com/wp-content/uploads/2023/10/Endless-RNA-scaled.jpg)
Cambridge, Mass., October 19, 2023 – In a pioneering move, Flagship Pioneering announces the fusion of Laronde and Senda Biosciences, birthing Sail Biomedicines—a trailblazing force in the evolution of fully programmable medicines poised to redefine patient care. Dr. Guillaume Pfefer, Ph.D., and MBA, the current CEO-Partner at Flagship Pioneering, will spearhead Sail as its CEO and board member, with Dr. John Mendlein, Executive Partner at Flagship Pioneering, assuming the role of Executive Chairman.
Sail Biomedicines leverages over eight years of collaborative data and platform development from Laronde and Senda Biosciences. Senda’s platform, utilizing a universal chemical code within natural nanoparticles, allows precise deployment of payloads, like translatable RNA, to designated cells.
Simultaneously, Laronde’s groundbreaking Endless RNA (eRNA), a synthetic RNA class, presents substantial therapeutic potential.
Dr. Mendlein underscores the potential of Endless RNA to inaugurate a new era of programmable medicines, deliverable to cells and tissues through unique deployment molecules. He envisions leveraging proprietary generative AI technologies and rapid prototyping as pivotal for achieving breakthroughs beyond current human comprehension.
Dr. Pfefer highlights Sail’s deployment platform, utilizing natural nanoparticles to transport biomolecules into human cells with unique tropism, potency, and redosability. His vision is to expedite the development of new product candidates, form strategic partnerships, and unlock diverse value pools for the swift delivery of transformative vaccines and therapies.
Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering, expresses confidence in Sail Biomedicines, stating, “I am confident the combined leadership team and board will carry forward this company to realize its bold ambitions and ultimately deliver maximum impact for patients.”
The Sail Biomedicines Board of Directors, including Drs. Mendlein and Pfeffer, comprises individuals from the Laronde and Senda Biosciences boards, alongside experts from Incyte, ADC Therapeutics, Massachusetts Institute of Technology, and Flagship Pioneering.
About Sail Biomedicines
Sail Biomedicines pioneers the integrative design and deployment of fully programmable medicines, combining programmable circular RNA technology (Endless RNA™ or eRNA) with an industry-leading platform of programmable nanoparticles.
About Flagship Pioneering
Flagship Pioneering is a biotechnology company inventing and building platform companies, each harboring the potential for transformative products in human health or sustainability. Since 2000, Flagship has shepherded over 100 ventures, resulting in over $90 billion in aggregate value, with a current ecosystem comprising 43 companies.
![GMP mRNA](https://static.packgene.com/wp-content/uploads/2023/05/GMP-mRNA.jpg)
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)